Gene Editing Markets by Application, Technology, Place, Industry and Product with Executive and Consultant Guides 2025 to 2029
Gene Editing Markets | Global coverage | Market size | Actionable insights| Trends | Key companies | Growth forecasts
Gene Editing, particularly through tools like CRISPR, is rapidly advancing across various fields of biotechnology. Initially focused on medical applications, such as altering genes in human cells, it has already led to the cure of previously incurable diseases, with more breakthroughs anticipated. This swift progress is driving a surge in new applications spanning multiple industries, offering fresh opportunities with each technological leap. As this innovation trajectory continues, it is crucial to grasp the diverse prospects emerging in the near and long term. Understanding and aligning with realistic growth expectations is key.
Our research empowers you to become the go-to expert within your organization for navigating these transformative developments.
About the Author:
Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
This report provides detailed, actionable insights into the Gene Editing market for the period 2025 to 2029 and includes the following:
- Gene editing market structure
- Healthcare spending perspective
- Market trends
- Factors driving growth
- Factors limiting growth
- Recent developments in gene editing
- Key gene editing company profiles
- Global gene editing market forecasts by:
- Country: USA, Canada, Germany, France, UK, rest of Europe, Japan, China, South Korea, rest of APAC, Brazil, Mexico, rest of LATAM, Middle East and Africa, Global (additional country breakouts can be provided on request)
- Application: Cell Line, Plant, Animal, Cell Therapy, Gene Therapy, Diagnostics, Research, Other
- Technology: CRISPR, Talens, ZFN, Meganuclease, Other
- Industry: Pharmaceutical, Clinial, Academic, Contract, Other
- Product: Instruments, Cells, Reagents, Other
Pricing options
- $6,995: single-user (encrypted file - one user/device)
- $10,495: multi-user (encrypted file - up to 5 users/devices)
- $13,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that publications meet the expectations of our demanding customers.
10x Genomics
4D Molecular Therapeutics
Abeona Therapeutics
Acrigen Biosciences
Adarx Pharmaceuticals
Adverum Biotechnologies
Affini-T Therapeutics
Agilent Technologies
Arbor Biotechnologies
Arcturus Therapeutics
Axxam
Beam Therapeutics
Beckman Coulter Diagnostics (Danaher)
Becton, Dickinson and Company (BD)
Binx Health
bioMérieux Diagnostics
Bio-Rad Laboratories
Bluebird Bio
Caribou Biosciences
Cell Microsystems
Cellenion (BICO)
Century Therapeutics
Chroma Medicine
Creative Biogene
Crispr Therapeutics
Editas Medicine
ERS Genomics
FASMAC
Genscript Biotech
Illumina
Inscripta
Intellia Therapeutics
J&J Innovative Medicine
Locus Biosciences
Mammoth Biosciences
Metagenomi
Myllia Biotechnology
Namocell
NRGene
Poseida Therapeutics
Precision Biosciences
Prime Medicine
Proof Diagnostics
Regeneron Pharmaceuticals
Revvity
Roche Diagnostics
Sherlock Biosciences
Thermo Fisher Scientific
Twist Bioscience
Verve Therapeutics
Vivlion
Wave Life Science
Methodology
This report is based on research conducted over the last four months. Data is derived primarily from executive comments, quarterly reports, and industry association data. While much information is kept confidential by suppliers this report infers revenues based on estimates of individual company activities by channel historically, currently, and as intermittently reported. This report aggregates supplier revenues and compares these to industry and other sources to arrive at estimates of current and historical market size. Forecasts are firstly based on historical growth rates and the current overall economic growth outlook for specific regions and countries. Secondarily the growth outlook is modified to account for factors specific to the market under study as
explained in the Situation Analysis.
Sources
Sources of information include the World Health Organization, the International Monetary Fund, the World Bank, several U.S. and European Union government bodies and industry associations. Considerable primary information is collected from company annual and quarterly reports, industry associations, industry participants and executives, whose information and insight are regularly solicited. Much company information comes from company websites, investor presentations, press releases, annual reports, 10K filings, news reports, national statistical services and industry blogs. Technical information is primarily based on published academic literature.
Author
The principal author of this report holds a M.B.A. in Finance and Strategy from the University of British Columbia. He also holds a B.Sc. in Chemistry
from the same university. He is a graduate of the Harvard Business School program Finance for Senior Executives. He is a graduate of The Burke Institute Seminar in Market Research. He has worked in clinical laboratory research and testing in a hands-on capacity. He is a co-author of the paper The Radioimmunoassay of Angiotensinogen II by Antibody Trapping. He has considerable experience in mergers, acquisitions, and business development.
